Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by MADDEN SECURITIES Corp

MADDEN SECURITIES Corp trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 45.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,200 shares of the medical research company’s stock after selling 2,630 shares during the period. MADDEN SECURITIES Corp’s holdings in Charles River Laboratories International were worth $591,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cetera Investment Advisers boosted its stake in Charles River Laboratories International by 2.4% during the 2nd quarter. Cetera Investment Advisers now owns 9,969 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 229 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Charles River Laboratories International during the third quarter worth about $79,000. Exchange Traded Concepts LLC grew its stake in Charles River Laboratories International by 26.4% in the third quarter. Exchange Traded Concepts LLC now owns 6,049 shares of the medical research company’s stock worth $1,191,000 after purchasing an additional 1,264 shares in the last quarter. Creative Planning increased its holdings in Charles River Laboratories International by 4.0% in the third quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock valued at $920,000 after buying an additional 180 shares during the last quarter. Finally, Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International during the third quarter valued at approximately $32,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Monday, February 3rd. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective for the company. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a report on Monday, November 18th. UBS Group reaffirmed a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Stock Down 2.4 %

CRL opened at $159.90 on Tuesday. The stock’s 50 day moving average price is $179.79 and its 200 day moving average price is $192.80. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The stock has a market cap of $8.18 billion, a P/E ratio of 20.01, a P/E/G ratio of 6.47 and a beta of 1.37. Charles River Laboratories International, Inc. has a 12 month low of $157.41 and a 12 month high of $275.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).